CANAGLIFLOZIN HEMIHYDRATE
Get in touch with us!
Get in touch with us!
An Overview
SODIUM-GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITOR
Treatment of adults with insufficiently controlled type 2 diabetes mellitus to lower blood sugar levels, reduce the risk of stroke, heart attack or death and decrease the risk of end-stage kidney failure, worsening kidney function, need for hospitalization for heart failure and cardiovascular death.
Description / Use
- Product type: antidiabetic.
- CAS number: 928672-86-0.
- Common indications: type 2 diabetes mellitus.
- Product status: development.
- Available grades: current PSD: D10 < 5µm; D50 ‹ 10µm; D9O < 50µm.
Properties
- Oral administration.
- Rapid absorption (1-2h).
- Potential global treatment candidates about 150 million people.
- CAGR (2023-2033) over +2.7%.
Advantages
- Polymorphic Form I (EMA/374133/2013) confirmed.
- Purity > 98%.
- Two impurities identified.
- Total impurities around 0.1%. Stable room temperature.
Final Product Innovator Presentations
- Monotherapy: Canagliflozin hemihydrate 100 mg; 300 mg.
- Combined: Canagliflozin hemihydrate / Metformin hydrochloride 50 mg/850 mg; 50 mg/1.000 mg; 150 mg/850 mg; 150 mg/1.000 mg.
Functional benefits
- Can be applied in patients with cardiac and vascular disease and severe renal insufficiency.
- Similar efficacy than other products of the same family.
- Higher security due to less hypoglycemia risk than other products for same therapeutic line.
* Items covered by valid patents are not offered or supplied for commercial use. Products under patent are available for R&D use only.
Certifications












Our API
Canagliflozin
- Our API canagliflozin is manufactured in accordance with cGMP and stringent international quality standards.
Canagliflozin
- Our API canagliflozin is manufactured in accordance with cGMP and stringent international quality standards.